Seminars in Diagnostic Pathology
Volume 23, Issue 2 , Pages 61-62 , May 2006

Introduction

References 

  1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580
  2. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–1056
  3. Welsh RA, Meyer AT. Ultrastructure of gastric leiomyoma. Arch Pathol. 1969;87:71–81
  4. Evans DJ, Lampert IA, Jacobs M. Intermediate filaments in smooth muscle tumours. J Clin Pathol. 1983;36:57–61
  5. Appelman H, Helwig EB. Cellular leiomyomas of the stomach in 49 patients. Arch Pathol Lab Med. 1977;101:373–377
  6. Mazur MT, Clark HB. Gastric stromal tumors (Reappraisal of histogenesis). Am J Surg Pathol. 1983;7:507–519
  7. van de Rijn M, Hendrickson MR, Rouse RV. CD34 expression by gastrointestinal tract stromal tumors. Hum Pathol. 1994;25:766–771
  8. Kitamura Y, Hirota S. Kit as a human oncogenic tyrosine kinase. Rev Cell Mol Life Sci. 2004;61:2924–2931
  9. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710
  10. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480
  11. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8:3034–3038
  12. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25–35

PII: S0740-2570(06)00145-6

doi: 10.1053/j.semdp.2006.09.003

Seminars in Diagnostic Pathology
Volume 23, Issue 2 , Pages 61-62 , May 2006

Article Tools